<!DOCTYPE html>
<html lang="en">
<head>        <meta charset="utf-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">    <link
        rel="stylesheet"
        href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css"
        integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm"
        crossorigin="anonymous"
    />
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/c3/0.6.12/c3.min.css"/>
    <style>
        h2 {
            margin-top: 35px;
        }

        html, body {
            height: 100%;
        }

        body {
            display: flex;
            flex-flow: column;
        }

        .footer {
            margin-top: auto;
            padding-top: 1em;
            background-color: #f5f5f5;
        }
    </style>    <title>KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_UNKN_AGE_IMM_WITH_ARR_VS_IMM_BY_RRR_PRIMARY_IMMUNIZ_WITH_RECOMB_ADENOVIRUS_35_1DY_UP</title></head>

<body>
<nav class="navbar navbar-expand-lg navbar-light bg-light">
    <span class="navbar-brand">
        Molecular Signatures Database
    </span>
</nav>

<div class="container" style="margin-top: 50px; margin-bottom: 50px">
<div class="card">
        <div class="card-header">
            KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_UNKN_AGE_IMM_WITH_ARR_VS_IMM_BY_RRR_PRIMARY_IMMUNIZ_WITH_RECOMB_ADENOVIRUS_35_1DY_UP
        </div>
        <div class="card-body">
                <p>RTS,S is an advanced malaria vaccine candidate and confers significant protection against &lt;i&gt;Plasmodium falciparum&lt;/i&gt; infection in humans. Little is known about the molecular mechanisms driving vaccine immunity. Here, we applied a systems biology approach to study immune responses in subjects receiving three consecutive immunizations with RTS,S (RRR), or in those receiving two immunizations of RTS,S/AS01 following a primary immunization with adenovirus 35 (Ad35) (ARR) vector expressing circumsporozoite protein. Subsequent controlled human malaria challenge (CHMI) of the vaccinees with &lt;i&gt;Plasmodium&lt;/i&gt;-infected mosquitoes, 3 wk after the final immunization, resulted in ~50% protection in both groups of vaccinees. Circumsporozoite protein (CSP)-specific antibody titers, prechallenge, were associated with protection in the RRR group. In contrast, ARR-induced lower antibody responses, and protection was associated with polyfunctional CD4&lt;sup&gt;+&lt;/sup&gt; T-cell responses 2 wk after priming with Ad35. Molecular signatures of B and plasma cells detected in PBMCs were highly correlated with antibody titers prechallenge and protection in the RRR cohort. In contrast, early signatures of innate immunity and dendritic cell activation were highly associated with protection in the ARR cohort. For both vaccine regimens, natural killer (NK) cell signatures negatively correlated with and predicted protection. These results suggest that protective immunity against &lt;i&gt;P. falciparum&lt;/i&gt; can be achieved via multiple mechanisms and highlight the utility of systems approaches in defining molecular correlates of protection to vaccination.</p>
            <dl>
                <dt>Local Unique Identifier</dt>
                <dd><a href="https://bioregistry.io/msigdb:M41021">M41021</a>
                </dd>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            in taxon (<code>RO:0002162</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/NCBITaxon:9606">NCBITaxon:9606</a></li>
                        </ol>
                    </dt>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            has part (<code>BFO:0000051</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/ncbigene:3429">ncbigene:3429</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:10964">ncbigene:10964</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:2537">ncbigene:2537</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:8820">ncbigene:8820</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:710">ncbigene:710</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:400941">ncbigene:400941</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:4061">ncbigene:4061</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:2048">ncbigene:2048</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3959">ncbigene:3959</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:6614">ncbigene:6614</a></li>
                        </ol>
                    </dt>
            </dl>
            <span class="badge badge-warning">Term generation via PyOBO is currently under construction</span>
            <blockquote>
                Term(reference=Reference(prefix=&#39;msigdb&#39;, identifier=&#39;M41021&#39;, name=&#39;KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_UNKN_AGE_IMM_WITH_ARR_VS_IMM_BY_RRR_PRIMARY_IMMUNIZ_WITH_RECOMB_ADENOVIRUS_35_1DY_UP&#39;), definition=&#39;RTS,S is an advanced malaria vaccine candidate and confers significant protection against &lt;i&gt;Plasmodium falciparum&lt;/i&gt; infection in humans. Little is known about the molecular mechanisms driving vaccine immunity. Here, we applied a systems biology approach to study immune responses in subjects receiving three consecutive immunizations with RTS,S (RRR), or in those receiving two immunizations of RTS,S/AS01 following a primary immunization with adenovirus 35 (Ad35) (ARR) vector expressing circumsporozoite protein. Subsequent controlled human malaria challenge (CHMI) of the vaccinees with &lt;i&gt;Plasmodium&lt;/i&gt;-infected mosquitoes, 3 wk after the final immunization, resulted in ~50% protection in both groups of vaccinees. Circumsporozoite protein (CSP)-specific antibody titers, prechallenge, were associated with protection in the RRR group. In contrast, ARR-induced lower antibody responses, and protection was associated with polyfunctional CD4&lt;sup&gt;+&lt;/sup&gt; T-cell responses 2 wk after priming with Ad35. Molecular signatures of B and plasma cells detected in PBMCs were highly correlated with antibody titers prechallenge and protection in the RRR cohort. In contrast, early signatures of innate immunity and dendritic cell activation were highly associated with protection in the ARR cohort. For both vaccine regimens, natural killer (NK) cell signatures negatively correlated with and predicted protection. These results suggest that protective immunity against &lt;i&gt;P. falciparum&lt;/i&gt; can be achieved via multiple mechanisms and highlight the utility of systems approaches in defining molecular correlates of protection to vaccination.&#39;, provenance=[Reference(prefix=&#39;pubmed&#39;, identifier=&#39;28193898&#39;, name=None)], relationships=defaultdict(&lt;class &#39;list&#39;&gt;, {TypeDef(reference=Reference(prefix=&#39;RO&#39;, identifier=&#39;0002162&#39;, name=&#39;in taxon&#39;), comment=None, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=None, holds_over_chain=None): [Reference(prefix=&#39;NCBITaxon&#39;, identifier=&#39;9606&#39;, name=&#39;Homo sapiens&#39;)], TypeDef(reference=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000051&#39;, name=&#39;has part&#39;), comment=&#39;Inverse of part_of&#39;, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000050&#39;, name=&#39;part of&#39;), holds_over_chain=None): [Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3429&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;10964&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2537&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;8820&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;710&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;400941&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;4061&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2048&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3959&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;6614&#39;, name=None)]}), properties=defaultdict(&lt;class &#39;list&#39;&gt;, {&#39;category_code&#39;: [&#39;C7&#39;], &#39;sub_category_code&#39;: [&#39;VAX&#39;], &#39;contributor&#39;: [&#39;HIPC SIGNATURES&#39;], &#39;exact_source&#39;: [&#39;Fig S2C&#39;], &#39;external_details_url&#39;: [&#39;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338562/figure/sfig02/&#39;]}), parents=[], synonyms=[], xrefs=[], alt_ids=[], namespace=None, is_obsolete=False)
            </blockquote>
        </div>
    </div></div>

<footer class="footer">
    <p class="small text-center text-muted">
        Generated with PyOBO
    </p>
</footer>

<script src="https://code.jquery.com/jquery-3.2.1.slim.min.js"
        integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN"
        crossorigin="anonymous"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js"
        integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl"
        crossorigin="anonymous"></script></body>
</html>